<DOC>
	<DOC>NCT01413386</DOC>
	<brief_summary>Paclitaxel covered metal biliary stent is non-inferior to common covered metal biliary stent in their patency rate and safety at the 6 months after stenting.</brief_summary>
	<brief_title>Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent</brief_title>
	<detailed_description>Paclitaxel covered metal biliary stent (Niti-S Mira-Cover II Biliary Stent) is non-inferior to common covered metal biliary stent (Niti-S Biliary Stent_ComVi type)in their patency rate and safety at the 6 months after stenting.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient who submitted a written informed consent for the this trial, and 18 ~ 90 years old Patient who have pancreatic cancer and/or biliary cancer with mid or distal CBD invasion Patient who is inoperable and/or unresectable cases of malignant pancreatic stenosis Patient who is attempting of endoscopic biliary metallic stenting (by ERBD) firstly Patient who have life expectancy at least longer than 3 months (Karnofsky score &gt;60%) Patient who previously had surgical biliary drainage Patient who carrying bleeding disorder Patient who have combined Hilar and/or intrahepatic duct cancer Patient who is improper to endoscopic treatment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>paclitaxel</keyword>
	<keyword>drug eluting stent</keyword>
</DOC>